|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$1,927,240
|
N/A
|
National Institutes of Health
|
|
NATIONAL FOOD AND NUTRIENT ANALYSIS PROGRAM (NFNAP) DIETARY NUTRIENTS
|
ACN18004-001
|
$225,000
|
$22,500
|
-, -
|
UNITED STATES DEPT OF AGRICULTURE
|
|
Novel platform linking cancer-specific glycosylation with cell signaling outcomes
|
1R21CA229044-01
|
$225,250
|
$112,625
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Glycomics Laboratory for the Development of Ovarian Cancer Biomarkers
|
1U01CA226055-01
|
$768,101
|
$768,101
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Postmenopausal women's alcohol study
|
ZIA CP000101-10336
|
$43,293
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Case-Control Study
|
ZIA CP000185-10318
|
$18,664
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
The Golestan Cohort Study
|
ZIA CP000185-10361
|
$31,091
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
Detection of somatic, subclonal and mosaic CNVs from sequencing
|
1U24CA220242-01A1
|
$559,916
|
$279,958
|
ABYZOV, ALEXEJ
|
MAYO CLINIC ROCHESTER
|
|
Li-Fraumeni Syndrome in Brazil
|
ZIA CP010144-10769
|
$12,981
|
|
Achatz, Maria Isabel
|
DCEG (NCI)
|
|
A practical and versatile high-resolution 3D dosimetry system for clinical use
|
1R41CA217421-01A1
|
$299,962
|
|
ADAMOVICS, JOHN
|
HEURIS, INC.
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
5R50CA211280-03
|
$215,047
|
$107,524
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
|
5R01CA211648-02
|
$432,788
|
$432,788
|
ADLI, MAZHAR
|
UNIVERSITY OF VIRGINIA
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
$67,374
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-03S1
|
$154,939
|
$3,099
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$2,907
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
$18,444
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
1K08CA218420-01
|
$177,120
|
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Nucleotide Metabolism in Senescence and Platinum Resistance of Ovarian Cancer
|
5R00CA194309-04
|
$210,465
|
$210,465
|
AIRD, KATHERINE
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
$24,473
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Development of novel gallium-68 bisphosphonate for imaging bone metastases in prostate cancer
|
1R43CA221580-01
|
$225,000
|
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
|
1F30CA220847-01
|
$49,044
|
|
ALI, MOIEZ
|
DUKE UNIVERSITY
|
|
Multicellular Cancer Cell Cluster Extravasation through Angiopellosis
|
1F31CA217153-01A1
|
$34,660
|
|
ALLEN, TYLER
|
NORTH CAROLINA STATE UNIVERSITY RALEIGH
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
5U01CA202144-04
|
$741,952
|
$370,976
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Tumor Plasticity
|
1R35CA220446-01
|
$900,000
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
$18,525
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
$26,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
$343,926
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Novel Markers for Disease Outcome in Breast Cancer
|
ZIA BC 010887
|
$519,415
|
|
Ambs, Stefan
|
CCR (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
$37,654
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Effects of Physical Activity Calorie Expenditure (PACE) Food Labeling
|
3R01CA184473-04S1
|
$45,615
|
|
AMMERMAN, ALICE
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Targeting angiogenesis and vasculogenic mimicry in Triple Negative Breast Cancer
|
1R43CA195882-01A1
|
$300,000
|
|
Ammons, William
|
SYNERGYS BIOTHERAPEUTICS, INC.
|
|
Womens Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S3
|
$175,562
|
$28,090
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Molecular Studies of Cellular Cytotoxicity
|
ZIA BC 010013
|
$791,415
|
|
Anderson, Stephen
|
CCR (NCI)
|
|
General Descriptive Studies
|
ZIA CP010183-00350
|
$521,314
|
|
Anderson, William
|
DCEG (NCI)
|
|
Defining the Transcriptional Regulation and Genomic Organization of FAIM3 and PIGR, Human Ig Receptors Involved in Immunity, Auto-Immune Disease, and Lymphoma
|
1F31CA221012-01
|
$29,954
|
|
ANDREWS, JARED
|
WASHINGTON UNIVERSITY
|
|
Nuclear Factor-kappaB in Ovarian Cancer
|
ZIA BC 011054
|
$480,705
|
$480,705
|
Annunziata, Christina
|
CCR (NCI)
|
|
Clinical trials in women's cancers
|
ZIA BC 011584
|
$192,282
|
$134,597
|
Annunziata, Christina
|
CCR (NCI)
|
|
Clinical trials in women's cancers
|
ZIA BC 011584
|
$206,100
|
$144,270
|
Annunziata, Christina
|
CCR (NCI)
|
|
Immune cell control of ovarian cancer
|
ZIA BC 011775
|
$288,423
|
$288,423
|
Annunziata, Christina
|
CCR (NCI)
|
|
Immune cell control of ovarian cancer
|
ZIA BC 011775
|
$309,150
|
$309,150
|
Annunziata, Christina
|
CCR (NCI)
|
|
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
|
1R01CA196988-01A1
|
$353,419
|
$353,419
|
ANTALIS, TONI
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
|
5R01CA196988-02
|
$353,419
|
$353,419
|
ANTALIS, TONI
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Descriptive studies of cancer and mortality
|
ZIA CP010150-10763
|
$31,498
|
|
Apelberg, Meredith
|
DCEG (NCI)
|
|
Collaborative Pathways that Lead to Leukemia
|
ZIA BC 010982
|
$443,718
|
|
Aplan, Peter
|
CCR (NCI)
|
|
Pre-clinical Studies of Therapy for Myelodysplastic Syndrome
|
ZIA BC 010983
|
$380,330
|
|
Aplan, Peter
|
CCR (NCI)
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$536,543
|
|
Apolo, Andrea
|
CCR (NCI)
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
$30,265
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Regulation and Function of WIP1 Phosphatase and its Role in Tumor Cells
|
ZIA BC 011197
|
$583,055
|
$291,527
|
Appella, Ettore
|
CCR (NCI)
|
|
LINE-1 genotoxicity and cytotoxicity and its relevance to cancer
|
1F30CA221175-01
|
$49,044
|
$16,185
|
ARDELJAN, DANIEL
|
JOHNS HOPKINS UNIVERSITY
|
Total relevant funding to Ovarian Cancer for this search: $127,845,829
|